Following a recent decision from the U.S. Court of Appeals for the Ninth Circuit in Khoja v. Orexigen Therapeutics, Inc., plaintiffs alleging securities fraud against companies in the pharmaceutical and life sciences sector...more
6/18/2019
/ Adverse Events ,
Defense Strategies ,
Extrinsic Evidence ,
Food and Drug Administration (FDA) ,
Life Sciences ,
Litigation Strategies ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Pre-Trial Motions ,
Prescription Drugs ,
Securities Fraud ,
Securities Litigation ,
Stock Drop Litigation
On December 6, 2016, the Supreme Court of the United States ruled unanimously in State Farm Fire and Casualty Co. v. United States ex rel. Rigsby that violations of the False Claims Act’s (FCA) seal requirement do not require...more